Core Points - IM Cannabis Corp. has agreed to reduce the exercise price of its November 2024 Warrants from C$4.32 to C$3.43 and extend their expiration date from November 12, 2026, to July 31, 2030 [1] - The company has filed a resale registration statement with the SEC for an aggregate of 4,982,517 common shares, which includes shares from various warrants and options [3][4] - The transaction involving the reduction and extension of the warrants was approved by the independent members of the board of directors [8] Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on providing premium cannabis products to medical patients [22] - The company leverages a data-driven approach and a globally sourced product supply chain to enhance its commercial and brand power [22] - IM Cannabis operates through subsidiaries in Israel, importing and distributing cannabis, and also runs medical cannabis retail pharmacies and distribution centers [23]

Core Viewpoint - Cannabis stocks experienced a significant increase, driven by reports that former President Trump is considering reclassifying cannabis as a lower-risk substance [1] Group 1: Stock Performance - Tilray Brands (TLRY.US) surged over 15% [1] - Veru Inc (VERU.US) also rose more than 15% [1] - Harrow (HROW.US) increased by over 5% [1] - Canopy Growth (CGC.US) saw a rise of over 3% [1]

Group 1 - American cannabis stocks have surged recently due to President Donald Trump's consideration of reclassifying marijuana from a Schedule I drug [1] - The article emphasizes the importance of observing megatrends and how they can provide insights into investment opportunities as society and technologies evolve [1] - The focus on fundamentals, quality of leadership, and product pipeline is crucial for identifying potential investment opportunities in the cannabis industry [1] Group 2 - The author has experience in evaluating startups and emerging industries, which adds credibility to the analysis of the cannabis market [1] - The article highlights the significance of marketing and business strategy, particularly for medium-sized companies and startups within the cannabis sector [1]

Financial Performance - Village Farms International, Inc. reported strong financial results with an increase in revenues and net income [1] - The privatization of its US fresh produce segment in May has led to successful outcomes reflected in Q2 performance [1] Industry Insights - The article is part of a monthly report on the cannabis industry, indicating ongoing interest and analysis in this sector [2] - The author has experience in technical stock analysis and emerging markets, suggesting a focus on investment strategies within the cannabis industry [2]

Financial Performance - Record gross revenue of $110.2 million, a 73% increase year-over-year and a 7.2% sequential increase[86] - Record net revenue of $70.8 million, a 72% increase year-over-year and a 7.9% sequential increase[86] - Adjusted EBITDA of $5.7 million, a 64% increase year-over-year and a 16% sequential increase[86] - International revenue reached $7.4 million, a 208% increase year-over-year and a 21% sequential increase[86] - Free cash flow was $5.0 million, compared to ($4.8) million in the prior year period[86] Strategic Initiatives - Completed the acquisition of Motif Labs Ltd, expecting approximately $15 million in run-rate cost synergies[44] - Completed the acquisition of Collective Project Limited, fast-tracking entry into the cannabinoid beverages category and the U S market[47] - Strategic investments from BAT totaled over $345 million to fund research & development and international M&A[48] - Invested $21 million into German cannabis leader Sanity Group to establish a foothold in the rapidly growing German market and expand export volume to Europe[61] - 27% of flower harvest at Moncton facility was seed-based in Q3 Fiscal 2025[65] Market Position - Organigram is the 1 LP in market share in Canada[17] - 1 in vapes, 1 in pre-rolls, 1 in milled flower, 1 in hash, 3 in edibles, 3 in dried flower in Canada[86]

Core Insights - Vireo Growth Inc. reported a significant increase in Q2 GAAP revenue, reaching $48.1 million, a 91% year-over-year growth, primarily driven by completed merger transactions [1][2] - The company's pro forma financial results aligned with management's expectations, with pro forma revenue and adjusted EBITDA estimated at $90.7 million and $23.2 million, respectively [3][6] - A recent refinancing of $153 million has positioned the company with a competitive cost of capital and over $100 million in cash, enhancing its financial stability [1][7] Financial Performance - Q2 GAAP revenue was $48.1 million, up from $25.1 million in Q2 2024, marking a 91.4% increase [2] - GAAP gross profit for Q2 was $20.4 million, a 50% increase from $13.6 million in the same quarter last year [2] - The gross profit margin decreased to 42.5% from 54.0% year-over-year [2] - Adjusted gross profit was $24.8 million, reflecting an 82.4% increase compared to $13.6 million in Q2 2024 [2] - SG&A expenses rose to $12.2 million, a 61.5% increase from $7.6 million in Q2 2024 [2] Mergers and Acquisitions - The company successfully closed three merger transactions during Q2, acquiring WholesomeCo in Utah, Proper Brands in Missouri, and Deep Roots Harvest in Nevada, which expanded its operational footprint to six states [4][5] - These acquisitions have positioned Vireo as one of the largest multi-state cannabis operators in the U.S. [5] Balance Sheet and Liquidity - As of June 30, 2025, total current assets were $186.2 million, including cash of $106.2 million, while total current liabilities were $51.8 million [8] - The company had a total of 1,058,617,377 shares outstanding at a share price of $0.52 [8] Future Outlook - Management expressed confidence in the company's growth trajectory following the merger transactions and refinancing, indicating a strong position for future acquisitions and industry leadership [3][6]

NEW YORK and TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCID: ITHUF), which owns, operates, and partners with regulated cannabis operations across the United States, today reported its financial results for the second quarter ended June 30, 2025. The Company’s Quarterly Report on Form 10-Q (the “Quarterly Report”), which includes its unaudited interim condensed consolidated financial statements for the three and six months ended June 30 ...

Core Viewpoint - Cannabis stocks and ETFs experienced significant gains following reports that U.S. President Donald Trump is considering reclassifying marijuana to a less restrictive category, which could have major implications for the industry [1][2]. Industry Impact - The potential reclassification would move marijuana from Schedule I to Schedule III, allowing cannabis companies to claim standard business tax deductions and credits, expand access to banking, and facilitate more medical research [2][6]. - A Schedule III classification could ease banking restrictions, providing businesses with better access to banking services and attracting more investors [6]. - The reclassification could shift public perception, further legitimizing the medical cannabis industry and paving the way for broader acceptance and use of marijuana as a therapeutic agent [6][7]. - Nearly 40 states in the U.S. have already legalized marijuana in various capacities, and a federal shift could encourage more states to consider legalization [7]. Market Reaction - Following the news, cannabis stocks saw substantial increases: Trulieve Cannabis Corp. surged 35%, Tilray jumped 32%, Curaleaf Holdings climbed 29%, and Canopy Growth gained 24% [3]. - In the ETF market, Roundhill Cannabis ETF rose 29.4%, Amplify Seymour Cannabis ETF increased by 27.8%, and Amplify Alternative Harvest ETF gained 27.0% [4]. ETF Details - **Roundhill Cannabis ETF (WEED)**: Concentrated exposure to leading U.S. cannabis companies, with an asset base of $6.4 million and an average daily trading volume of 42,000 shares [9]. - **Amplify Seymour Cannabis ETF (CNBS)**: Actively managed fund with diversified U.S. exposure, holding 32 securities and an asset base of $76.2 million, trading an average of 11,000 shares daily [10]. - **Amplify Alternative Harvest ETF (MJ)**: First ETF focusing on the global cannabis industry, with an asset base of $128.5 million and an average daily volume of 54,000 shares [12]. - **AdvisorShares Pure US Cannabis ETF (MSOS)**: Actively managed ETF focusing on U.S. companies, with an asset base of $521 million and an average daily volume of $9.4 million shares [13]. - **AdvisorShares Pure Cannabis ETF (YOLO)**: Actively managed fund with a focus on both domestic and foreign cannabis equity securities, holding 22 stocks with an asset base of $31.3 million and an average daily volume of 55,000 shares [14].

Group 1 - cbdMD, Inc. will host a conference call on August 14, 2025, at 4:20 p.m. Eastern Time to discuss its financial results for the third quarter of fiscal year 2025, ending June 30, 2025 [2][3] - The company is recognized as one of the leading and most trusted CBD brands in the United States, offering a comprehensive line of THC-free CBD products and Delta 9 products compliant with the Farm Act [2][3] - cbdMD's product range includes Paw CBD for pets, ATRx functional mushroom products, and Herbal Oasis, a THC-infused social seltzer designed for wellness and connection [2][3] Group 2 - The conference call can be accessed via specific dial-in numbers for USA/Canada and international participants, with a replay available for a limited time [3] - The company emphasizes its commitment to producing high-quality, U.S.-grown, THC-free CBD products, which are formulated using validated scientific methods [4]

Trulieve Cannabis (TCNN.F) FY Conference Summary Industry Overview - The conference focused on the U.S. cannabis industry, highlighting the regulatory landscape and potential changes in marijuana classification [1][2] - Trulieve Cannabis is identified as a U.S. multistate operator in the cannabis space [1] Key Points on Regulatory Reform - The Trump administration is considering rescheduling marijuana, which has generated excitement among investors [3][10] - Currently classified as a Schedule I drug, marijuana is recognized as having no accepted medical use and a high risk of abuse, similar to heroin [5][6] - In August 2023, the HHS recommended reclassifying marijuana to Schedule III, acknowledging its medical value [7] - The rescheduling process involves public comments, with 43,000 submissions favoring the change [8] - The new DEA administrator and the retirement of the administrative law judge have influenced the rescheduling process [9] - Rescheduling would not legalize marijuana but would facilitate research and reduce tax burdens on cannabis companies [11][12] - The industry faces challenges such as limited access to capital and difficulties for employees in obtaining loans and mortgages [14][15] Florida Adult Use Market - Trulieve is actively involved in the Smart and Safe Florida campaign for adult use legalization in the 2026 election [20][23] - Changes in campaign strategy include protecting children from targeted advertising, banning public smoking, and allowing additional operator licenses [24][25] - The campaign has gathered over 660,000 signatures, with a deadline of February 2026 for the required 880,000 [28] - The Florida Supreme Court will review the ballot language by April 1, 2026 [30] Product Strategy and Consumer Trends - Trulieve focuses on customer experience, achieving high Net Promoter Scores (NPS) [31] - There has been a shift in consumer preference towards value-tier products due to inflationary pressures [33] - The company has adapted its promotional strategies to offer more approachable pricing and bundle deals [34] - The introduction of hemp-derived THC beverages has opened new market opportunities, reaching consumers who may not seek medical cannabis [40][41] - The Onward and Upward beverage lines are designed to provide social alternatives without hangovers [42][43] Capital Allocation and Financial Strategy - Trulieve has $368 million in private placement notes due in October 2026, with plans to refinance part of this debt [46][48] - The company is investing in the Smart and Safe Florida campaign and focusing on organic growth and potential acquisitions [49] - Capital expenditures for the year are projected at $40 million, primarily for store openings and remodels [49] - The board regularly discusses share buybacks, but the focus has been on reinvesting in the business [51]